Yüklüyor......
Advances in the management of HER2-positive early breast cancer
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast can...
Kaydedildi:
| Yayımlandı: | Crit Rev Oncol Hematol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662944/ https://ncbi.nlm.nih.gov/pubmed/29042085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.critrevonc.2017.10.001 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|